Osimertinib in EGFR Mutation-Positive Advanced NSCLC

被引：25
|
作者：
不详
机构：
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 378卷 / 13期
关键词：
PARAGANGLIOMA;
D O I：
10.1056/NEJMc1801669
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1260 / 1261
页数：2
相关论文
共 50 条
  • [41] Development of a Fluorinated Analogue of Erlotinib for PET Imaging of EGFR Mutation-Positive NSCLC
    Shamni, Ofer
    Grievink, Hilbert
    Itamar, Batel
    Mishani, Eyal
    Abourbeh, Galith
    MOLECULAR IMAGING AND BIOLOGY, 2019, 21 (04) : 696 - 704
  • [42] Precision targeted therapy for EGFR mutation-positive NSCLC: Dilemmas and coping strategies
    Meng, Ying
    Bai, Rilan
    Cui, Jiuwei
    THORACIC CANCER, 2023, 14 (13) : 1121 - 1134
  • [43] Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis
    Popat, Sanjay
    Mok, Tony
    Yang, James Chih-Hsin
    Wu, Yi-Long
    Lungershausen, Juliane
    Stammberger, Uz
    Griebsch, Ingolf
    Fonseca, Tiago
    Paz-Ares, Luis
    LUNG CANCER, 2014, 85 (02) : 230 - 238
  • [44] Real-World Management of Patients with EGFR Mutation-Positive NSCLC in the US
    Li, Y.
    Appius, A.
    Pattipaka, T.
    Feyereislova, A.
    Cassidy, A.
    Ganti, A. K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2216 - S2216
  • [45] Patterns of progression on first-line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
    Schuler, A.
    Huser, J.
    Schaer, S.
    Schmid, S.
    Scherz, A.
    Gautschi, O.
    Mauti, L. A.
    Von Briel, T.
    Waibel, C.
    De Nicola, L. Wannesson
    Pankovics, J.
    Mark, M. T.
    Rothschild, S. I.
    Addeo, A.
    Janthur, W-D.
    Siano, M.
    Britschgi, C.
    Frueh, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1585
  • [46] Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC
    Mok, T.
    Nakagawa, K.
    Rosell, R.
    Lee, K.
    Corral, J.
    Migliorino, M. R.
    Pluzanski, A.
    Linke, R.
    Devgan, G.
    Sbar, E.
    Quinn, S.
    Wang, T.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S454 - S454
  • [47] Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients with EGFR Mutation-Positive Advanced NSCLC
    Halmos, B.
    Tan, E.
    Soo, R.
    Cadranel, J.
    Lee, M. K.
    Foucher, P.
    Hsia, T.
    Hochmair, M.
    Griesinger, F.
    Hida, T.
    Kim, E.
    Melosky, B.
    Maerten, A.
    Carcereny, E.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S470 - S471
  • [48] Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
    Jebbink, M.
    de Langen, A. J.
    Monkhorst, K.
    Boelens, M. C.
    van den Broek, D.
    van der Noort, V.
    de Gooijer, C. J.
    Mahn, M.
    van der Wekken, A. J.
    Hendriks, L.
    Hashemi, S. M. S.
    Paats, M. S.
    Dingemans, A. C.
    Smit, E. F.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (04):
  • [49] Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies
    Jang, Seong Bok
    Kim, Kyeong Bae
    Sim, Sujin
    Cho, Byoung Chul
    Ahn, Myung-Ju
    Han, Ji-Youn
    Kim, Sang -We
    Lee, Ki Hyeong
    Cho, Eun Kyung
    Haddish-Berhane, Nahor
    Mehta, Jaydeep
    Oh, Se-Woong
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (10):
  • [50] Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
    Nobuyuki Yamamoto
    Takeshi Mera
    Angela Märten
    Maximilian J. Hochmair
    Advances in Therapy, 2020, 37 : 759 - 769
12345